Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b open-label study of CCX872-B in pancreatic adenocarcinoma
NL-OMON42021Phase 1Active, not recruiting
- Sponsor
- ChemoCentryx
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ccx872-b in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by ChemoCentryx. Primary endpoint: Progression-free survival. Started Apr 2015; status: active, not recruiting.
02
Drugs
ccx872-b
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NL-OMON42021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42021.